Part 2: To what extent can T cells expand in vitro?
For cell sorter developers it is critical to specify cell numbers and associated sort rates in order to select the right technology; your development has to target the right ball park!
In this post, we continue our examination of the numbers of cells that will need to be sorted in the next generation of autologous cell therapies. The previous post looked at numbers of cells in a dose. Now we will look at expansion in vitro.
The fact that T cells can expand by a vast amount in-vivo (> 1000-fold), is a well known feature of the adaptive immune system, and is essential for our immune response to viral infections. Naive T cells can undergo 20-30 doublings before they reach immunosenescence, which translates to a 106 – 109-fold expansion (Weng et al. 1995; Shen et al. 2007). If T-cells could be practically expanded 106-fold in vitro, a T-cell therapy of 1010 cells would only need 104 cells before expansion, which would be quite easy to produce using existing cell sorting technologies.
However, the more important question is: to what extent can T-cells expand in an effective cell therapy? T-cells are known to become exhausted, especially in vitro. T-cell exhaustion is associated with telomere shortening, a process which occurs faster in vitro than in vivo. Evidence suggests T-cells cultured for short times are more active than T-cells which have been expanded to their limits (Melenhorst 2009; Zhou et al. 2005; Shen et al. 2007).
Moreover, other exciting cell therapies are based on tumour-infiltrating lymphocytes (TILs) rather than naive cells. TILs have been shown to expand 103-fold in vitro (Dudley et al. 2003). Assuming a 1010 total cell dose, 103-fold expansion and 1% sort fraction of the input PBMCs, then 109 PBMCs need to be sorted, which is impractical with current instrumentation.
The current leaders of cell therapy all seem to be using relatively short times for their T-cell expansion step. Table 1 reviews their early work where the expansion protocols were published. All major labs seem to be culturing T-cells for 1 – 2 weeks, for around 6 – 8 doublings or 100 – 200-fold expansion. Besides the advantages of short culture period for T-cell activity, it is also desirable for manufacturing and delivery of the therapy.
Assuming a 1010 total cell dose, 10% sort fraction and 100-fold expansion, then 109 PBMCs would need to be sorted, which again is impractical on current instrumentation.
So we conclude that, although T-cells are intrinsically capable of vast expansion in vitro, current T-cell therapies are restricted to very modest expansions of 102 – 103-fold. For a defined cell therapy based on current dose levels, cell populations of around 109 cells need to be sorted – calling for a much faster cell sorter than any currently available.
Brentjens, Renier J., Isabelle Rivière, Jae H. Park, Marco L. Davila, Xiuyan Wang, Jolanta Stefanski, Clare Taylor, et al. 2011. “Safety and Persistence of Adoptively Transferred Autologous CD19-Targeted T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias.” Blood 118 (18): 4817–28. doi:10.1182/blood-2011-04-348540.
Dudley, Mark E., John R. Wunderlich, Thomas E. Shelton, Jos Even, and Steven A. Rosenberg. 2003. “Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients.” Journal of Immunotherapy (Hagerstown, Md. : 1997) 26 (4): 332–42.
Hollyman, Daniel, Jolanta Stefanski, Mark Przybylowski, Shirley Bartido, Oriana Borquez-Ojeda, Clare Taylor, Raymond Yeh, et al. 2009. “Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy.” Journal of Immunotherapy (Hagerstown, Md. : 1997) 32 (2): 169–80. doi:10.1097/CJI.0b013e318194a6e8.
Johnson, Laura A., Richard A. Morgan, Mark E. Dudley, Lydie Cassard, James C. Yang, Marybeth S. Hughes, Udai S. Kammula, et al. 2009. “Gene Therapy with Human and Mouse T-Cell Receptors Mediates Cancer Regression and Targets Normal Tissues Expressing Cognate Antigen.” Blood 114 (3): 535–46. doi:10.1182/blood-2009-03-211714.
Kalos, Michael, Bruce L. Levine, David L. Porter, Sharyn Katz, Stephan A. Grupp, Adam Bagg, and Carl H. June. 2011. “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia.” Science Translational Medicine 3 (95): 95ra73. doi:10.1126/scitranslmed.3002842.
Melenhorst, J. Joseph. 2009. “Optimizing T-Cell Expansion: Have We Reached the Limit?” Cytotherapy 11 (7): 813–14. doi:10.3109/14653240903387163.
Morgan, Richard A., Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James C. Yang, Richard M. Sherry, Richard E. Royal, et al. 2006. “Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.” Science (New York, N.Y.) 314 (5796): 126–29. doi:10.1126/science.1129003.
Porter, David L., Bruce L. Levine, Michael Kalos, Adam Bagg, and Carl H. June. 2011. “Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia.” The New England Journal of Medicine 365 (8): 725–33. doi:10.1056/NEJMoa1103849.
Shen, Xinglei, Juhua Zhou, Karen S. Hathcock, Paul Robbins, Daniel J. Powell, Steven A. Rosenberg, and Richard J. Hodes. 2007. “Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length.” Journal of Immunotherapy (Hagerstown, Md. : 1997) 30 (1): 123–29. doi:10.1097/01.cji.0000211321.07654.b8.
Weng, N P, B L Levine, C H June, and R J Hodes. 1995. “Human Naive and Memory T Lymphocytes Differ in Telomeric Length and Replicative Potential.” Proceedings of the National Academy of Sciences of the United States of America 92 (24): 11091–94.
Zhou, Juhua, Xinglei Shen, Richard J. Hodes, Steven A. Rosenberg, and Paul F. Robbins. 2005. “Telomere Length of Transferred Lymphocytes Correlates with in Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy.” Journal of Immunology (Baltimore, Md. : 1950) 175 (10): 7046–52.
Samson Rogers leads Cellular Highways, TTP’s initiative in therapeutic cell sorting. He has previously worked on a variety of life science technologies at TTP, co-founded two startups, and published research papers on techniques of measuring biomolecules and cells. Samson has a PhD from Cambridge and an MBA from the ESMT.